Tyrosine kinase inhibitors in glioblastoma (Homo sapiens)

From WikiPathways

Revision as of 03:18, 11 November 2024 by Eweitz (Talk | contribs)
Jump to: navigation, search


Description

"Therapeutic tyrosine kinase inhibitors and anti-EGFR monoclonal antibodies in glioblastoma anti-EGFR mAbs bind the EGFR extracellular domain, preventing EGFR dimerization and subsequent activation. Tyrosine kinase inhibitors (TKIs) target the intracellular TK domain, blocking subsequent receptor tyrosine kinase pathways (RTKs)" From Figure F3 in https://pmc.ncbi.nlm.nih.gov/articles/PMC10967338.

Try the New WikiPathways

View approved pathways at the new wikipathways.org.

Quality Tags

Ontology Terms

 

Bibliography

  1. Manzanares-Guzmán A, Lugo-Fabres PH, Camacho-Villegas TA; ''vNARs as Neutralizing Intracellular Therapeutic Agents: Glioblastoma as a Target.''; Antibodies, 2024 PubMed Europe PMC Scholia

History

View all...
CompareRevisionActionTimeUserComment
135824view14:13, 12 November 2024EgonwRemoved the publisher HQ location
135815view00:45, 12 November 2024EweitzRefine layering
135791view18:04, 11 November 2024EweitzOntology Term : 'drug pathway' added !
135779view04:40, 11 November 2024EweitzAdd ChEBI identifiers for TKIs
135778view04:30, 11 November 2024EweitzAdd PharmGKB identifiers
135777view03:49, 11 November 2024EweitzOntology Term : 'glial cell' added !
135776view03:41, 11 November 2024EweitzAdd RTK pathways
135775view03:28, 11 November 2024EweitzModified description
135774view03:18, 11 November 2024EweitzOntology Term : 'glioblastoma' added !
135773view03:09, 11 November 2024EweitzModified description
135772view02:58, 11 November 2024EweitzAdd literature reference
135771view02:33, 11 November 2024EweitzAdd more interactions, organelle, pathway containers
135767view20:03, 10 November 2024EweitzAdd more interactions
135766view19:55, 10 November 2024EweitzAdd interactions, labels
135765view17:35, 10 November 2024EweitzAdd more metabolites, identifiers
135764view14:17, 10 November 2024EweitzNew pathway

External references

DataNodes

View all...
NameTypeDatabase referenceComment
AKT1GeneProductENSG00000142208 (Ensembl)
AKT2GeneProductENSG00000105221 (Ensembl)
AKT3GeneProductENSG00000117020 (Ensembl)
AfatinibMetabolite
BTCGeneProductENSG00000174808 (Ensembl)
CetuximabMetabolite
DacomitinibMetaboliteCHEBI:132268 (ChEBI)
EGFGeneProductENSG00000138798 (Ensembl)
EGFRGeneProduct
EREGGeneProductENSG00000124882 (Ensembl) "EPR" originally
ErlotinibMetaboliteCHEBI:114785 (ChEBI)
GRB2GeneProductENSG00000177885 (Ensembl)
GefitinibMetaboliteCHEBI:49668 (ChEBI)
HRASGeneProductENSG00000174775 (Ensembl)
JAK / STAT pathwayPathway
JAK1GeneProductENSG00000162434 (Ensembl)
JAK2GeneProductENSG00000096968 (Ensembl)
JAK3GeneProductENSG00000105639 (Ensembl)
KRASGeneProductENSG00000133703 (Ensembl)
LapatinibMetabolite
MAP2K1GeneProductENSG00000107356 (Ensembl)
MAP2K2GeneProductENSG00000101418 (Ensembl)
MAP2K3GeneProductENSG00000107958 (Ensembl)
MAP2K4GeneProductENSG00000115669 (Ensembl)
MAP2K5GeneProductENSG00000138015 (Ensembl)
MAP2K6GeneProductENSG00000129652 (Ensembl)
MAP2K7GeneProductENSG00000118907 (Ensembl)
MTORGeneProductENSG00000198793 (Ensembl)
NRASGeneProductENSG00000213281 (Ensembl)
NeratinibMetabolite
PDK1GeneProductENSG00000152256 (Ensembl)
PI3K / Akt pathwayPathway
PIP2MetaboliteCHEBI:77276 (ChEBI)
PIP3MetaboliteCHEBI:16618 (ChEBI)
PTENGeneProductENSG00000171862 (Ensembl)
PanitumumabMetabolite
RAF1GeneProductENSG00000132155 (Ensembl)
RAS / MAPK pathwayPathway
RHEBGeneProductENSG00000106615 (Ensembl)
RPTORGeneProductENSG00000141564 (Ensembl)
SOS1GeneProductENSG00000115904 (Ensembl)
SOS2GeneProductENSG00000100485 (Ensembl)
STAT3GeneProductENSG00000168610 (Ensembl)
TGFAGeneProductENSG00000163235 (Ensembl)
TSC1GeneProductENSG00000165699 (Ensembl)
TSC2GeneProductENSG00000103197 (Ensembl)
TYK2GeneProductENSG00000105397 (Ensembl)

Annotated Interactions

No annotated interactions

Retrieved from "https://classic.wikipathways.org/index.php/Pathway:WP5494"
Personal tools